Lantern Pharma Inc., a clinical-stage biopharmaceutical company utilizing its proprietary RADR® AI and machine learning platform to revolutionize oncology drug discovery and development, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided key updates on its AI-driven drug candidates, enhancements to the RADR® platform for precision oncology, and other operational advancements.
